U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Anaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

MedGen UID:
927511
•Concept ID:
C4289979
•
Neoplastic Process

Definition

An anaplastic oligodendroglioma carrying IDH gene family mutation and combined whole-arm losses of 1p and 19q (1p/19q codeletion). [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVAnaplastic Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted

Professional guidelines

PubMed

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D, Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB, Ducray F, Preusser M, Wen PY
Neuro Oncol 2024 Oct 3;26(10):1805-1822. doi: 10.1093/neuonc/noae107. PMID: 38912846Free PMC Article
Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J, Schiff D
Curr Treat Options Oncol 2022 Sep;23(9):1219-1232. Epub 2022 Aug 1 doi: 10.1007/s11864-022-01000-z. PMID: 35913658
Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Halasz LM, Attia A, Bradfield L, Brat DJ, Kirkpatrick JP, Laack NN, Lalani N, Lebow ES, Liu AK, Niemeier HM, Palmer JD, Peters KB, Sheehan J, Thomas RP, Vora SA, Wahl DR, Weiss SE, Yeboa DN, Zhong J, Shih HA
Pract Radiat Oncol 2022 Sep-Oct;12(5):370-386. Epub 2022 May 31 doi: 10.1016/j.prro.2022.05.004. PMID: 35902341

Recent clinical studies

Etiology

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D, Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB, Ducray F, Preusser M, Wen PY
Neuro Oncol 2024 Oct 3;26(10):1805-1822. doi: 10.1093/neuonc/noae107. PMID: 38912846Free PMC Article
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN
JAMA Oncol 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. PMID: 36006639
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ
Neuro Oncol 2022 Sep 1;24(9):1471-1481. doi: 10.1093/neuonc/noac064. PMID: 35287169Free PMC Article
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest 2022 Feb;102(2):126-133. Epub 2021 Sep 9 doi: 10.1038/s41374-021-00667-6. PMID: 34504304
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network
Neuro Oncol 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124. PMID: 31832685Free PMC Article

Diagnosis

World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN
JAMA Oncol 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. PMID: 36006639
A review of adult-type diffuse gliomas in the WHO CNS5 classification with special reference to Astrocytoma, IDH-mutant and Oligodendroglioma, IDH-mutant and 1p/19q codeleted.
Santosh V, Rao S
Indian J Pathol Microbiol 2022 May;65(Supplement):S14-S23. doi: 10.4103/ijpm.ijpm_34_22. PMID: 35562130
HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.
Felix M, Friedel D, Jayavelu AK, Filipski K, Reinhardt A, Warnken U, Stichel D, Schrimpf D, Korshunov A, Wang Y, Kessler T, Etminan N, Unterberg A, Herold-Mende C, Heikaus L, Sahm F, Wick W, Harter PN, von Deimling A, Reuss DE
Neuro Oncol 2022 Dec 1;24(12):2121-2132. doi: 10.1093/neuonc/noac111. PMID: 35511748Free PMC Article
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
Brandner S, McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Leal ES, Faulkner CL, Palmer A, Wragg C, Jefferies S, Vale L, Higgins JPT, Kurian KM
Neuropathol Appl Neurobiol 2022 Jun;48(4):e12790. Epub 2022 Mar 3 doi: 10.1111/nan.12790. PMID: 34958131Free PMC Article
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest 2022 Feb;102(2):126-133. Epub 2021 Sep 9 doi: 10.1038/s41374-021-00667-6. PMID: 34504304

Therapy

The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?
van den Bent MJ, French PJ, Brat D, Tonn JC, Touat M, Ellingson BM, Young RJ, Pallud J, von Deimling A, Sahm F, Figarella Branger D, Huang RY, Weller M, Mellinghoff IK, Cloughsey TF, Huse JT, Aldape K, Reifenberger G, Youssef G, Karschnia P, Noushmehr H, Peters KB, Ducray F, Preusser M, Wen PY
Neuro Oncol 2024 Oct 3;26(10):1805-1822. doi: 10.1093/neuonc/noae107. PMID: 38912846Free PMC Article
T2-Fluid-attenuated inversion recovery (FLAIR) pseudoprogression in patients with anaplastic oligodendrogliomas treated with procarbazine, lomustine and vincristine (PCV) chemotherapy alone.
Esparragosa Vazquez I, Ndiaye M, Di Stefano AL, Younan N, Larrieu-Ciron D, Seyve A, Picart T, Meyronet D, Boutet C, Vassal F, Carpentier C, Figarella-Branger D, Dehais C, Forest F, Rivoirard R, Ducray F; POLA network
Eur J Neurol 2023 Sep;30(9):2879-2883. Epub 2023 May 31 doi: 10.1111/ene.15873. PMID: 37204066
Current Considerations in the Treatment of Grade 3 Gliomas.
Jo J, Schiff D
Curr Treat Options Oncol 2022 Sep;23(9):1219-1232. Epub 2022 Aug 1 doi: 10.1007/s11864-022-01000-z. PMID: 35913658
Characteristics of Anaplastic Oligodendrogliomas Short-Term Survivors: A POLA Network Study.
Garnier L, Vidal C, Chinot O, Cohen-Jonathan Moyal E, Djelad A, Bronnimann C, Bekaert L, Taillandier L, Frenel JS, Langlois O, Colin P, Menei P, Dhermain F, Carpentier C, Gerazime A, Curtit E, Figarella-Branger D, Dehais C, Ducray F
Oncologist 2022 May 6;27(5):414-423. doi: 10.1093/oncolo/oyac023. PMID: 35522558Free PMC Article
Molecular, Histological, and Clinical Characteristics of Oligodendrogliomas: A Multi-Institutional Retrospective Study.
Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY
Neurosurgery 2022 May 1;90(5):515-522. doi: 10.1227/neu.0000000000001875. PMID: 35179134Free PMC Article

Prognosis

Oligodendroglioma, IDH-mutant and 1p/19q-codeleted-prognostic factors, standard of care and chemotherapy, and future perspectives with neoadjuvant strategy.
Sasaki H, Kitamura Y, Toda M, Hirose Y, Yoshida K
Brain Tumor Pathol 2024 Apr;41(2):43-49. Epub 2024 Apr 2 doi: 10.1007/s10014-024-00480-1. PMID: 38564040
IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S, Broggi G, Barresi V
Histol Histopathol 2023 Jul;38(7):739-753. Epub 2023 Jan 9 doi: 10.14670/HH-18-582. PMID: 36651583
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN
JAMA Oncol 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. PMID: 36006639
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest 2022 Feb;102(2):126-133. Epub 2021 Sep 9 doi: 10.1038/s41374-021-00667-6. PMID: 34504304
CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas.
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D; POLA Network
Neuro Oncol 2019 Dec 17;21(12):1519-1528. doi: 10.1093/neuonc/noz124. PMID: 31832685Free PMC Article

Clinical prediction guides

IDH-mutant diffuse gliomas: tips and tricks in the era of genomic tumor classification.
Ammendola S, Broggi G, Barresi V
Histol Histopathol 2023 Jul;38(7):739-753. Epub 2023 Jan 9 doi: 10.14670/HH-18-582. PMID: 36651583
World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review.
Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN
JAMA Oncol 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. PMID: 36006639
PI3K/AKT/mTOR signaling pathway activity in IDH-mutant diffuse glioma and clinical implications.
Mohamed E, Kumar A, Zhang Y, Wang AS, Chen K, Lim Y, Shai A, Taylor JW, Clarke J, Hilz S, Berger MS, Solomon DA, Costello JF, Molinaro AM, Phillips JJ
Neuro Oncol 2022 Sep 1;24(9):1471-1481. doi: 10.1093/neuonc/noac064. PMID: 35287169Free PMC Article
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
Brandner S, McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Leal ES, Faulkner CL, Palmer A, Wragg C, Jefferies S, Vale L, Higgins JPT, Kurian KM
Neuropathol Appl Neurobiol 2022 Jun;48(4):e12790. Epub 2022 Mar 3 doi: 10.1111/nan.12790. PMID: 34958131Free PMC Article
Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.
Komori T
Lab Invest 2022 Feb;102(2):126-133. Epub 2021 Sep 9 doi: 10.1038/s41374-021-00667-6. PMID: 34504304

Recent systematic reviews

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
Halasz LM, Attia A, Bradfield L, Brat DJ, Kirkpatrick JP, Laack NN, Lalani N, Lebow ES, Liu AK, Niemeier HM, Palmer JD, Peters KB, Sheehan J, Thomas RP, Vora SA, Wahl DR, Weiss SE, Yeboa DN, Zhong J, Shih HA
Pract Radiat Oncol 2022 Sep-Oct;12(5):370-386. Epub 2022 May 31 doi: 10.1016/j.prro.2022.05.004. PMID: 35902341
Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive meta-analysis based on a Cochrane systematic review.
Brandner S, McAleenan A, Jones HE, Kernohan A, Robinson T, Schmidt L, Dawson S, Kelly C, Leal ES, Faulkner CL, Palmer A, Wragg C, Jefferies S, Vale L, Higgins JPT, Kurian KM
Neuropathol Appl Neurobiol 2022 Jun;48(4):e12790. Epub 2022 Mar 3 doi: 10.1111/nan.12790. PMID: 34958131Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...